These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

490 related articles for article (PubMed ID: 33588145)

  • 1. Long-term follow-up of blinatumomab in patients with relapsed/refractory Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukaemia: Final analysis of ALCANTARA study.
    Martinelli G; Boissel N; Chevallier P; Ottmann O; Gökbuget N; Rambaldi A; Ritchie EK; Papayannidis C; Tuglus CA; Morris JD; Stein A
    Eur J Cancer; 2021 Mar; 146():107-114. PubMed ID: 33588145
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study.
    Topp MS; Gökbuget N; Stein AS; Zugmaier G; O'Brien S; Bargou RC; Dombret H; Fielding AK; Heffner L; Larson RA; Neumann S; Foà R; Litzow M; Ribera JM; Rambaldi A; Schiller G; Brüggemann M; Horst HA; Holland C; Jia C; Maniar T; Huber B; Nagorsen D; Forman SJ; Kantarjian HM
    Lancet Oncol; 2015 Jan; 16(1):57-66. PubMed ID: 25524800
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term survival and T-cell kinetics in relapsed/refractory ALL patients who achieved MRD response after blinatumomab treatment.
    Zugmaier G; Gökbuget N; Klinger M; Viardot A; Stelljes M; Neumann S; Horst HA; Marks R; Faul C; Diedrich H; Reichle A; Brüggemann M; Holland C; Schmidt M; Einsele H; Bargou RC; Topp MS
    Blood; 2015 Dec; 126(24):2578-84. PubMed ID: 26480933
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complete Hematologic and Molecular Response in Adult Patients With Relapsed/Refractory Philadelphia Chromosome-Positive B-Precursor Acute Lymphoblastic Leukemia Following Treatment With Blinatumomab: Results From a Phase II, Single-Arm, Multicenter Study.
    Martinelli G; Boissel N; Chevallier P; Ottmann O; Gökbuget N; Topp MS; Fielding AK; Rambaldi A; Ritchie EK; Papayannidis C; Sterling LR; Benjamin J; Stein A
    J Clin Oncol; 2017 Jun; 35(16):1795-1802. PubMed ID: 28355115
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FDA Supplemental Approval: Blinatumomab for Treatment of Relapsed and Refractory Precursor B-Cell Acute Lymphoblastic Leukemia.
    Pulte ED; Vallejo J; Przepiorka D; Nie L; Farrell AT; Goldberg KB; McKee AE; Pazdur R
    Oncologist; 2018 Nov; 23(11):1366-1371. PubMed ID: 30018129
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term survival of patients with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab.
    Topp MS; Gökbuget N; Zugmaier G; Stein AS; Dombret H; Chen Y; Ribera JM; Bargou RC; Horst HA; Kantarjian HM
    Cancer; 2021 Feb; 127(4):554-559. PubMed ID: 33141929
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blinatumomab compared with standard of care for the treatment of adult patients with relapsed/refractory Philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia.
    Rambaldi A; Ribera JM; Kantarjian HM; Dombret H; Ottmann OG; Stein AS; Tuglus CA; Zhao X; Kim C; Martinelli G
    Cancer; 2020 Jan; 126(2):304-310. PubMed ID: 31626339
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blinatumomab treatment of older adults with relapsed/refractory B-precursor acute lymphoblastic leukemia: Results from 2 phase 2 studies.
    Kantarjian HM; Stein AS; Bargou RC; Grande Garcia C; Larson RA; Stelljes M; Gökbuget N; Zugmaier G; Benjamin JE; Zhang A; Jia C; Topp MS
    Cancer; 2016 Jul; 122(14):2178-85. PubMed ID: 27143254
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blinatumomab vs historic standard-of-care treatment for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukaemia.
    Gökbuget N; Dombret H; Giebel S; Brüggemann M; Doubek M; Foa R; Hoelzer D; Kim C; Martinelli G; Parovichnikova E; Maria Ribera J; Schoonen M; Tuglus C; Zugmaier G; Bassan R
    Eur J Haematol; 2020 Apr; 104(4):299-309. PubMed ID: 31876009
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estimating Long-Term Survival of Adults with Philadelphia Chromosome-Negative Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia Treated with Blinatumomab Using Historical Data.
    Barlev A; Lin VW; Katz A; Hu K; Cong Z; Barber B
    Adv Ther; 2017 Jan; 34(1):148-155. PubMed ID: 27873237
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of blinatumomab in Chinese adults with Ph-negative relapsed/refractory B-cell precursor acute lymphoblastic leukemia: A multicenter open-label single-arm China registrational study.
    Zhou H; Yin Q; Jin J; Liu T; Cai Z; Jiang B; Li D; Sun Z; Li Y; He Y; Ma L; Gao S; Hu J; He A; Du X; Liu D; Zhang X; Ke X; Zhuang J; Han Y; Wang X; Chen Y; Gordon P; Yu D; Zugmaier G; Wang J
    Hematology; 2022 Dec; 27(1):917-927. PubMed ID: 36000952
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular response with blinatumomab in relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
    Gökbuget N; Kantarjian HM; Brüggemann M; Stein AS; Bargou RC; Dombret H; Fielding AK; Heffner L; Rigal-Huguet F; Litzow M; O'Brien S; Zugmaier G; Gao S; Nagorsen D; Forman SJ; Topp MS
    Blood Adv; 2019 Oct; 3(20):3033-3037. PubMed ID: 31648325
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia.
    Topp MS; Gökbuget N; Zugmaier G; Klappers P; Stelljes M; Neumann S; Viardot A; Marks R; Diedrich H; Faul C; Reichle A; Horst HA; Brüggemann M; Wessiepe D; Holland C; Alekar S; Mergen N; Einsele H; Hoelzer D; Bargou RC
    J Clin Oncol; 2014 Dec; 32(36):4134-40. PubMed ID: 25385737
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blinatumomab for Acute Lymphoblastic Leukemia Relapse after Allogeneic Hematopoietic Stem Cell Transplantation.
    Stein AS; Kantarjian H; Gökbuget N; Bargou R; Litzow MR; Rambaldi A; Ribera JM; Zhang A; Zimmerman Z; Zugmaier G; Topp MS
    Biol Blood Marrow Transplant; 2019 Aug; 25(8):1498-1504. PubMed ID: 31002989
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase 1b/2 study of blinatumomab in Japanese adults with relapsed/refractory acute lymphoblastic leukemia.
    Kiyoi H; Morris JD; Oh I; Maeda Y; Minami H; Miyamoto T; Sakura T; Iida H; Tuglus CA; Chen Y; Dos Santos C; Kalabus J; Anderson A; Hata T; Nakashima Y; Kobayashi Y
    Cancer Sci; 2020 Apr; 111(4):1314-1323. PubMed ID: 31971321
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Blinatumomab: A First-in-Class Bispecific T-Cell Engager for Precursor B-Cell Acute Lymphoblastic Leukemia.
    Buie LW; Pecoraro JJ; Horvat TZ; Daley RJ
    Ann Pharmacother; 2015 Sep; 49(9):1057-67. PubMed ID: 26041811
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of minimal residual disease response and of status of disease on survival after blinatumomab in B-cell acute lymphoblastic leukemia: results from a real-life study.
    Leotta S; Markovic U; Duminuco A; Mulè A; Porretto F; Federico V; Gentile M; Pastore D; Nigro LL; Selleri C; Serio B; Calafiore V; Patti C; Mauro E; Vetro C; Maugeri C; Parisi M; Fiumara P; Parrinello L; Marino S; Scuderi G; Garibaldi B; Musso M; Renzo ND; Vigna E; Martino EA; Raimondo FD; Milone G
    Ann Hematol; 2024 Sep; 103(9):3701-3712. PubMed ID: 38609726
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blinatumomab as first salvage versus second or later salvage in adults with relapsed/refractory B-cell precursor acute lymphoblastic leukemia: Results of a pooled analysis.
    Topp MS; Stein AS; Gökbuget N; Horst HA; Boissel N; Martinelli G; Kantarjian H; Brüggemann M; Chen Y; Zugmaier G
    Cancer Med; 2021 Apr; 10(8):2601-2610. PubMed ID: 33734596
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of blinatumomab versus salvage chemotherapy in relapsed or refractory Philadelphia-chromosome-negative B-precursor acute lymphoblastic leukemia from a US payer perspective.
    Delea TE; Amdahl J; Boyko D; Hagiwara M; Zimmerman ZF; Franklin JL; Cong Z; Hechmati G; Stein A
    J Med Econ; 2017 Sep; 20(9):911-922. PubMed ID: 28631497
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of blinatumomab: a real world data.
    Apel A; Ofran Y; Wolach O; Shimony S; Ram R; Levi I; Zektser M; Koren-Michowitz M
    Ann Hematol; 2020 Apr; 99(4):835-838. PubMed ID: 32076826
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.